- $30.55m
- $25.17m
- $18.79m
Annual cashflow statement for Nephros, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.87 | -7.11 | -1.57 | 0.074 | 1.19 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 1.31 | 3.29 | 1.02 | 0.851 | 0.725 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.883 | 0.229 | 1.17 | -1.55 | -0.413 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -1.42 | -3.23 | 0.827 | -0.492 | 1.65 |
| Capital Expenditures | -0.036 | -0.137 | -0.075 | -0.055 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.049 | 0 | — | 0.005 | 0 |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.085 | -0.137 | -0.075 | -0.05 | 0 |
| Financing Cash Flow Items | 0 | -0.031 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.237 | 0.034 | -0.079 | -0.005 | -0.005 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.28 | -3.34 | 0.673 | -0.547 | 1.64 |